Goals: We studied the prevalence and predictors of small-intestinal bacterial overgrowth (SIBO) in Crohn's disease (CD) outpatients and the relationship between SIBO and intestinal and/or systemic inflammation VSports手机版. .

Background: The relationship of SIBO with systemic and intestinal inflammation in CD patients is unclear. V体育安卓版.

Study: In this cross-sectional study, conducted between June, 2013 and January, 2015, 92 CD patients and 97 controls with nonchronic gastrointestinal complaints were assessed for the presence of SIBO using the H2/CH4 glucose breath test V体育ios版. Multivariate logistic regression was performed to investigate the potential association between SIBO and demographic, disease-related data, systemic markers of inflammation (C-reactive protein, and erythrocyte sedimentation rate), and biomarker of intestinal inflammation [fecal calprotectin concentration (FCC)]. .

Results: The SIBO rate was significantly higher in CD patients than in controls (32. 6% vs. 12. 4%, respectively, P=0. 0008). Patients with and without SIBO were comparable with regard to demographics, systemic inflammatory biomarkers, and disease characteristics, except for the stricturing phenotype being more common in SIBO-positive CD patients (43. 3% vs VSports最新版本. 19. 3%, P=0. 015). Notably, FCC was significantly higher in SIBO-positive patients (median of 485. 8 vs. 132. 7 μg/g; P=0. 004). Patients presenting increased FCC and stricturing disease had an odds of 9. 43 (95% confidence interval, 3. 04-11. 31; P<0. 0001) and 3. 83 (95% confidence interval, 1. 54-6. 75; P=0. 025) respectively, for SIBO diagnosis. .

Conclusions: In CD patients, SIBO is a highly prevalent condition V体育平台登录. Stricturing phenotype and increased FCC were strongly and independently associated with the presence of SIBO. SIBO diagnostic work-up followed by directed treatment is recommended in CD patients who present stricturing disease, especially in those with concurrent intestinal inflammation. .